Trials / Unknown
UnknownNCT00004293
Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (planned)
- Sponsor
- National Center for Research Resources (NCRR) · NIH
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
OBJECTIVES: I. Evaluate the efficacy and toxicity of glucocerebrosidase enzyme therapy in patients with Gaucher disease.
Detailed description
PROTOCOL OUTLINE: Patients are treated with intravenous glucocerebrosidase every 2 weeks. The dose is based on clinical severity of disease and response to therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | glucocerebrosidase |
Timeline
- Start date
- 1999-11-01
- First posted
- 1999-10-19
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00004293. Inclusion in this directory is not an endorsement.